OBJECTIVES: Helicobacter pylori eradication is recognized as the initial therapy for gastric low-grade, B-cell, mucosa-associated lymphoid tissue (MALT) lymphoma. This study assesses (i) the H. pylori eradication rates for various first- and second-line and rescue therapies and (ii) the associated reinfection rates in patients. METHODS: Pooled data analysis of systematic review of the literature was performed in this study. RESULTS: Data from 34 studies with 1,271 treated patients were used. After first-line therapy, the infection was cured in 91% (95% confidence interval (CI)=89.4-92.5) of cases, the eradication rate being higher after dual therapy compared with the 7- or 14-day triple therapies (P=0.0525). After second-line therapy, the eradication rate was 80.8% (95% CI=82.7-95.1), being higher after triple rather than quadruple therapy. Further therapies (from three to five attempts) cured the infection in 75% of patients. H. pylori infection was ultimately cured in 1,250 patients, resulting in eradication rates of 98.3% (95% CI=97.6-99) and 99.8% (95% CI=99.6-100) at intention-to-treat and per-protocol analysis levels, respectively. Bacterial reinfection occurred in 18 (2.7%; 95% CI=1.4-3.9) of 676 patients who were followed-up (0.7% yearly). Overall, gastric lymphoma remission was achieved in 973 (77.8%) of 1,250 patients successfully cured of H. pylori infection. CONCLUSIONS: This was the first comprehensive ( approximately 1,300 patients) analysis of the therapeutic management of H. pylori in gastric lymphoma patients. Data suggest that this infection is easily managed in these patients, being cured in nearly all cases.
OBJECTIVES:Helicobacter pylori eradication is recognized as the initial therapy for gastric low-grade, B-cell, mucosa-associated lymphoid tissue (MALT) lymphoma. This study assesses (i) the H. pylori eradication rates for various first- and second-line and rescue therapies and (ii) the associated reinfection rates in patients. METHODS: Pooled data analysis of systematic review of the literature was performed in this study. RESULTS: Data from 34 studies with 1,271 treated patients were used. After first-line therapy, the infection was cured in 91% (95% confidence interval (CI)=89.4-92.5) of cases, the eradication rate being higher after dual therapy compared with the 7- or 14-day triple therapies (P=0.0525). After second-line therapy, the eradication rate was 80.8% (95% CI=82.7-95.1), being higher after triple rather than quadruple therapy. Further therapies (from three to five attempts) cured the infection in 75% of patients. H. pyloriinfection was ultimately cured in 1,250 patients, resulting in eradication rates of 98.3% (95% CI=97.6-99) and 99.8% (95% CI=99.6-100) at intention-to-treat and per-protocol analysis levels, respectively. Bacterial reinfection occurred in 18 (2.7%; 95% CI=1.4-3.9) of 676 patients who were followed-up (0.7% yearly). Overall, gastric lymphoma remission was achieved in 973 (77.8%) of 1,250 patients successfully cured of H. pyloriinfection. CONCLUSIONS: This was the first comprehensive ( approximately 1,300 patients) analysis of the therapeutic management of H. pylori in gastric lymphomapatients. Data suggest that this infection is easily managed in these patients, being cured in nearly all cases.
Authors: Xavier Sagaert; Eric Van Cutsem; Gert De Hertogh; Karel Geboes; Thomas Tousseyn Journal: Nat Rev Gastroenterol Hepatol Date: 2010-05-04 Impact factor: 46.802
Authors: Werner Dolak; Barbara Kiesewetter; Leonhard Müllauer; Marius Mayerhoefer; Marlene Troch; Michael Trauner; Michael Häfner; Markus Raderer; Andreas Püspök Journal: Surg Endosc Date: 2015-10-20 Impact factor: 4.584
Authors: Yoon Jin Choi; Dong Ho Lee; Ji Yeon Kim; Ji Eun Kwon; Jae Yeon Kim; Hyun Jin Jo; Cheol Min Shin; Hyun Young Kim; Young Soo Park; Nayoung Kim; Hyun Chae Jung; In Sung Song Journal: Clin Endosc Date: 2011-12-31
Authors: Julong Cheng; Ali Torkamani; Rajesh K Grover; Teresa M Jones; Diana I Ruiz; Nicholas J Schork; Michael M Quigley; F Wesley Hall; Daniel R Salomon; Richard A Lerner Journal: Proc Natl Acad Sci U S A Date: 2011-03-17 Impact factor: 11.205